Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05914376 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Oct 11, 2025 to Jul 2, 2025
    • Study completion date: Nov 2025 to Jun 10, 2027
    v8
  2. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Jun 2025 to Oct 11, 2025
    • Site details revised at 2 of 2 sites
    v7
  3. Primary completion date: Mar 2025 to Jun 2025v6
  4. Interventions: Recombinant human IL-21 oncolytic vaccinia virus injection (Biological) to Recombinant human IL-21-expressing oncolytic vaccinia virus injection (Biological)
    • Study title expanded, about 1 word
    v5
  5. Study sites revised (2)v4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 2023 to Jul 5, 2023
    • Site details revised at 2 of 2 sites
    v3
  2. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to evaluate the safety, tolerance, pharmacokinetics, and biological properties of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced solid tumors.
Trial Details
NCT Number NCT05914376
Lead Sponsor Hangzhou Converd Co., Ltd.
Conditions
(from sponsor)		 Advanced Solid Tumors
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov